The results revealed that EMAP II+CD22+% cells in NHL subjects with advanced stage (stages III and IV) were higher compared with patients with intermediate-risk disease but with no significance [median: 6.3% (range: 3.6-7) % vs. 5.5% (range: 2.2-7) %; P = 0.218] (Table 4). This evidence concerns the gene AIMP1 and non-Hodgkin lymphoma.